mercredi 13 décembre 2017

Onco Actu du 13 décembre 2017

1. Biologie

Roswell Park Research Suggests New Strategy for Unleashing Cancer-Fighting Power of p53 Gene [Roswell Park Cancer Institute]

Cancer-causing mutation suppresses immune system around tumours [Institute of Cancer Research]

2.6 Etiologie - Environnement

Some facts about glyphosate [European Commission]

EU renews approval for herbicide glyphosate for five years [Reuters]

3.1 Prévention - Tabac

Holding Tobacco Companies Accountable for Deceptive Ads [Cancer Research Catalyst]

Health warnings on cigarettes could deter young people [Cancer Research UK]

'Heat not burn' cigarettes still harmful to health, say government advisers [The Guardian]

"Heat-not-burn" tobacco may be safer but still a risk: UK panel [Reuters]

3.8 Prévention - Alimentation

Disclosures in Nutrition Research [JAMA]

4.2 Dép., diag. & prono. - Génome

How privacy policies affect genetic testing [MIT News]

5.12.7 Immunothérapies - vaccins

Aduro buries another cancer vaccine after CRS-207 joins the lineup of clinical disasters [EndPoints]

Aduro Biotech Provides Update on CRS-207 Programs [Aduro]

5.12.8 Immunothérapies - Economie

PsiOxus banks first milestone for BMS-backed cancer therapy [FierceBiotech]

5.2.1 Pharma - Partenariats

Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer [Puma]

5.3.4 Traitements - AMM (FDA, EMA)

Acalabrutinib Receives FDA Approval for Mantle Cell Lymphoma [NCI]


Myriad's BRACAnalysis CDx® Test Effectively Identified Metastatic Breast Cancer Patients with Improved Outcomes from Pfizer's PARP Inhibitor, Talazoparib [Myriad]

5.8.1 ASH - Communiqués

Late-Breaking Clinical Trials Signal New Therapeutic Options for Many Patients in the Near Term [ASH]

5.8.5 ASH - Myélome multiple

ASH: Johnson & Johnson scores big Darzalex win in first-line myeloma, slashing risks in half [FiercePharma]

DARZALEX® (daratumumab) Combination Regimen Significantly Improved Outcomes for Newly Diagnosed Multiple Myeloma Patients who are Transplant Ineligible [Janssen]

GSK hails progress on its most advanced cancer drug [The Telegraph]

5.8.6 ASH - Leucémies

ASH: AbbVie's Venclexta trounces chemo in Rituxan CLL combo study [FiercePharma]

Study identifies agent that can reverse resistance to targeted drug in some leukemia cell types [Dana-Farber Cancer Institute]

Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of care regimen in previously treated chronic lymphocytic leukaemia [Roche]

5.8.7 ASH - Lymphomes

ASH: Merck's Keytruda nabs speedy FDA review in non-Hodgkin lymphoma [FiercePharma]

6.1 Observation

Use of chemotherapy for early stage breast cancer declines [Stanford Medicine]

Fewer women getting chemotherapy for early stage breast cancer [UPI]

6.10.1 Politiques (USA)

Loss of net neutrality could harm research [Nature]

6.7.1 Bioinformatique

No, Google's AI Program Can't Build Your Genome Sequence [Forbes]